Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

695 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study.
Thein KZ, Karp DD, Tsimberidou A, Gong J, Sulovic S, Shah J, Milton DR, Hong DS, Janku F, McQuinn L, Stephen BA, Colen R, Carter BW, Yap TA, Piha-Paul SA, Fu S, Meric-Bernstam F, Naing A. Thein KZ, et al. Invest New Drugs. 2022 Apr;40(2):463. doi: 10.1007/s10637-021-01194-3. Invest New Drugs. 2022. PMID: 34731355 Free PMC article. No abstract available.
Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study.
Schuetze S, Rothe M, Mangat PK, Garrett-Mayer E, Meric-Bernstam F, Calfa CJ, Farrington LC, Livingston MB, Wentzel K, Behl D, Kier Y, Marr AS, von Mehren M, Press JZ, Thota R, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Schuetze S, et al. JCO Precis Oncol. 2024 Jul;8:e2400219. doi: 10.1200/PO.24.00219. JCO Precis Oncol. 2024. PMID: 39013131 Clinical Trial.
Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma.
Wu Y, Chen S, Yang X, Sato K, Lal P, Wang Y, Shinkle AT, Wendl MC, Primeau TM, Zhao Y, Gould A, Sun H, Mudd JL, Hoog J, Mashl RJ, Wyczalkowski MA, Mo CK, Liu R, Herndon JM, Davies SR, Liu D, Ding X, Evrard YA, Welm BE, Lum D, Koh MY, Welm AL, Chuang JH, Moscow JA, Meric-Bernstam F, Govindan R, Li S, Hsieh J, Fields RC, Lim KH, Ma CX, Zhang H, Ding L, Chen F. Wu Y, et al. Cancer Res. 2023 Dec 15;83(24):4161-4178. doi: 10.1158/0008-5472.CAN-23-0604. Cancer Res. 2023. PMID: 38098449 Free PMC article.
A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer.
Hong DS, Kurzrock R, Oh Y, Wheler J, Naing A, Brail L, Callies S, André V, Kadam SK, Nasir A, Holzer TR, Meric-Bernstam F, Fishman M, Simon G. Hong DS, et al. Clin Cancer Res. 2011 Oct 15;17(20):6582-91. doi: 10.1158/1078-0432.CCR-11-0430. Epub 2011 Aug 10. Clin Cancer Res. 2011. PMID: 21831956 Free PMC article. Clinical Trial.
Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial.
Gonzalez-Angulo AM, Meric-Bernstam F, Chawla S, Falchook G, Hong D, Akcakanat A, Chen H, Naing A, Fu S, Wheler J, Moulder S, Helgason T, Li S, Elias I, Desai N, Kurzrock R. Gonzalez-Angulo AM, et al. Clin Cancer Res. 2013 Oct 1;19(19):5474-84. doi: 10.1158/1078-0432.CCR-12-3110. Clin Cancer Res. 2013. PMID: 24089446 Free PMC article. Clinical Trial.
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit.
Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, Ajani J, Tang C, Hess K, Hamilton SR, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. Jardim DL, et al. Oncotarget. 2014 Apr 15;5(7):1837-45. doi: 10.18632/oncotarget.1828. Oncotarget. 2014. PMID: 24742823 Free PMC article. Clinical Trial.
Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms.
Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, Moulder S, Valero V, Schwaederle M, Yelensky R, Miller VA, Stephens MP, Meric-Bernstam F, Kurzrock R. Wheler JJ, et al. Oncotarget. 2014 May 15;5(9):2349-54. doi: 10.18632/oncotarget.1946. Oncotarget. 2014. PMID: 24811890 Free PMC article.
Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit.
de Melo Gagliato D, Jardim DL, Falchook G, Tang C, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Hess K, Roy-Chowdhuri S, Moulder S, Gonzalez-Angulo AM, Meric-Bernstam F, Hong DS. de Melo Gagliato D, et al. Clin Breast Cancer. 2014 Dec;14(6):468-74. doi: 10.1016/j.clbc.2014.06.001. Epub 2014 Jun 23. Clin Breast Cancer. 2014. PMID: 25065564 Free PMC article. Clinical Trial.
695 results